HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases. HR+/HER2 ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

The C-HR+ is Toyota’s latest electric SUV to launch in Norway, where nearly all cars sold today are EVs. Toyota calls it “the perfect electric SUV for Norwegian roads,” with a spacious interior and up ...

The Toyota C-HR+ will be the car that kicks this off. And while it was unveiled in Europe with specifications only for that market for now, it seems poised to be a hit in the United States as well ...

PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the ...

Toyota is preparing for its profits to take a big hit this year as Trump’s tariffs take effect. With uncertainty rising in the auto industry, Toyota said it’s “reviewing” its plans to sell 1.5 million ...

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY ...